Healthcare Services

A significant industry trend in the HER2-Negative Breast Cancer Market includes the Regulatory Approvals And Market Expansion In HER2-Negative Breast Cancer Treatments

April 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Much Is The HER2-Negative Breast Cancer Market Expected To Grow In Terms Of Market Value Between 2026 And 2030?

The her2-negative breast cancer market has demonstrated substantial growth in recent years. It is forecast to increase from $17.57 billion in 2025 to $18.95 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.9%. The expansion observed during the past period can be linked to factors such as higher breast cancer screening participation, greater recognition of hormone receptor-positive cancers, an increase in oncology treatment center availability, the existence of proven chemotherapy protocols, and a rise in clinical oncology research efforts.

The market for her2-negative breast cancer is projected to experience substantial expansion in the coming years. This market is anticipated to reach a valuation of $25.41 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.6%. Factors contributing to this anticipated growth include a heightened demand for individualized oncology treatments, the wider uptake of therapies guided by genomics, the broadening of immunotherapy development pipelines, a greater emphasis on enhancing progression-free survival, and increased financial commitment to the development of oncology drugs. Key trends anticipated during this period encompass the increasing use of tailored hormone therapy regimens, the expanding application of cdk4/6 inhibitors, the broader utilization of genomic testing to guide treatment choices, a growing incorporation of immunotherapy for advanced disease stages, and an intensified focus on multi-drug treatment approaches.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21203&type=smp

What Major Drivers Are Influencing Demand In The HER2-Negative Breast Cancer Market?

The increasing occurrence of breast cancer cases is anticipated to drive expansion within the HER2-negative breast cancer market in the foreseeable future. Breast cancer is characterized by the uncontrolled proliferation of atypical cells within breast tissue, typically originating in the ducts or lobules. This surge in breast cancer cases is linked to various elements, such as heightened awareness and enhanced screening techniques, which facilitate earlier and more frequent diagnosis. HER2-Negative Breast Cancer is vital for advancing research, offering insights into unique tumor biology and treatment approaches, and aiding in the creation of more targeted patient therapies. For example, the American Cancer Society, a professional organization based in the US, predicts that in 2025, the United States will see approximately 316,950 new cases of invasive breast cancer in women and 2,800 cases in men. Furthermore, an estimated 59,080 cases of ductal carcinoma in situ (DCIS) are expected to be diagnosed in women. Consequently, the escalating number of breast cancer diagnoses is propelling the growth of the HER2-negative breast cancer market.

What Major Segment Divisions Exist Within The HER2-Negative Breast Cancer Market?

The her2-negative breast cancer market covered in this report is segmented –

1) By Treatment Type: Chemotherapy, Hormone Therapy, Targeted Therapy, Immunotherapy

2) By Cancer Stage: Early Stage, Locally Advanced Stage, Metastatic Stage

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Chemotherapy: Anthracyclines, Taxanes, Platinum-Based Chemotherapy, Alkylating Agents, Antimetabolites

2) By Hormone Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Selective Estrogen Receptor Degraders (SERDs)

3) By Targeted Therapy: CDK4/6 Inhibitors, PI3K Inhibitors, PARP Inhibitors

4) By Immunotherapy: Immune Checkpoint Inhibitors, Tumor-Infiltrating Lymphocyte (TIL) Therapy

Which Upcoming Trends Are Expected To Influence The HER2-Negative Breast Cancer Market?

Leading companies in the HER2-negative breast cancer market are concentrating on obtaining regulatory clearances to introduce novel therapies, expand their product offerings, and strengthen their presence in the market. Regulatory approvals denote the official permission granted by government bodies, enabling companies to commercialize and distribute drugs or treatments after fulfilling criteria for safety, effectiveness, and quality. For example, in October 2024, Genentech Inc., a US-based biotechnology corporation, secured FDA approval for Itovebi (inavolisib) as a targeted therapy for advanced hormone receptor-positive (HR+), HER2-negative breast cancer with a PIK3CA mutation. This approval facilitates the use of Itovebi in conjunction with palbociclib and fulvestrant, substantially improving progression-free survival for patients compared to existing treatments. This new therapeutic approach provides a critical option for patients with limited treatment alternatives, highlighting the significance of biomarker testing to identify individuals who would most benefit from this therapy.

Which Companies Are Leading Innovation In The HER2-Negative Breast Cancer Market?

Major companies operating in the her2-negative breast cancer market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Amgen Inc., Daiichi Sankyo Company Limited, Jiangsu Hansoh Pharmaceutical Co. Ltd., BeiGene Ltd., Chipscreen Biosciences Ltd., F. Hoffmann-La Roche Ltd, PharmAbcine Inc., Adagene Inc., H3 Biomedicine Inc., Radius Health Inc., Zenith Epigenetics Ltd.

Read the full her2-negative breast cancer market report here:

https://www.thebusinessresearchcompany.com/report/her2-negative-breast-cancer-global-market-report

Which Region Shows The Strongest Potential For Future Growth In The HER2-Negative Breast Cancer Market?

North America was the largest region in the HER2-negative breast cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the her2-negative breast cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored HER2-Negative Breast Cancer Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21203&type=smp

Browse Through More Reports Similar to the Global HER2-Negative Breast Cancer Market 2026, By The Business Research Company

Breast Cancer Drugs Global Market Report

https://www.thebusinessresearchcompany.com/report/breast-cancer-drugs-global-market-report

Metastatic Hr Her2 Breast Cancer Global Market Report

https://www.thebusinessresearchcompany.com/report/metastatic-hr-her2-breast-cancer-global-market-report

Breast Cancer Diagnostics Global Market Report

https://www.thebusinessresearchcompany.com/report/breast-cancer-diagnostics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795